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Abstract While type 2 diabetes is well-known to be
associated with poorer cognitive performance, few studies
have reported on the association of metabolic syndrome
(MetS) and contributing factors, such as insulin-resistance
(HOMA-IR), low adiponectin-, and high C-reactive protein
(CRP)- levels. We studied whether these factors are related
to cognitive function and which of the MetS components
are independently associated. The study was embedded in
an ongoing family-based cohort study in a Dutch popula-
tion. All participants underwent physical examinations,
biomedical measurements, and neuropsychological testing.
Linear regression models were used to determine the
association between MetS, HOMA-IR, adiponectin levels,
CRP, and cognitive test scores. Cross-sectional analyses
were performed in 1,898 subjects (mean age 48 years,
43% men). People with MetS had signiﬁcantly higher
HOMA-IR scores, lower adiponectin levels, and higher
CRP levels. MetS and high HOMA-IR were associated
with poorer executive function in women (P = 0.03 and
P = 0.009). MetS and HOMA-IR are associated with
poorer executive function in women.
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Cognitive impairment is a common problem in the elderly
andanimportantpredictorofdementia(DSM-IV).Thereare
multiple risk factors contributing to cognitive decline. For
long, type 2 diabetes has been recognized as a major risk
factor of dementia [1]. Epidemiological studies indicate that
hyperinsulinemia and insulin-resistance, which characterize
type 2 diabetes, may cause cognitive dysfunction [2, 3].
Insulin-resistance is also a feature of the metabolic syn-
drome (MetS) and there is increasing interest in the role of
MetS in cognition. The syndrome is deﬁned as the presence
of at least 3 out of 5 factors, which include central obesity,
hyperglycemia, hypertension, hypertriglyceridemia, and
low high-density lipoprotein cholesterol (HDL-c) levels
[4].Ithasahighprevalenceofover22%inWesternsocieties
[5], and is an important risk factor of cardiovascular disease
[6, 7]. Potentially, MetS is an important, modiﬁable, deter-
minant of cognitivepathology [8–10]. Previous studies have
shown associations between cognitive dysfunction and
MetS, but results are not consistent and predominantly
concern elderly people [11]. Of its individual components,
hypertension and hyperglycemia have proven to be the most
consistent determinants of cognitive function in a recent
review of published studies [12].
Adipose tissue also plays an important role in the
etiology of MetS. Adipose tissue functions as endocrine
tissue, among which secretion of adipocytokines and
cytokines, which indirectly affect C-reactive protein (CRP)
levels [13–15]. The visceral fat depot is thought to play an
important role in adipocytokine secretion and MetS [16].
Several groups have suggested that in particular adipo-
nectin might be a promising biomarker for MetS [17–19].
Whether it is related to cognitive function in humans is not
known, but animal studies indicate that adiponectin may
inﬂuence brain metabolism [20]. Regarding CRP levels, it
has been reported that the association of MetS with cog-
nitive function is stronger in those with high levels of CRP
[21, 22].
The MetS is an important health problem and may be a
suitable target for early intervention. The aim of the current
study was to examine whether the MetS and related factors,
insulin-resistance, plasma adiponectin and CRP-levels, are
related to cognitive function in a middle-aged population in
the Netherlands.
Methods
Study population
The study was performed in the Erasmus Rucphen Family
Study(ERF),whichisanongoingfamily-basedcohortstudy
in a genetically isolated population [23]. The ERF popula-
tion includes around 3,000 individuals, all living descen-
dents of 22 couples who, at the end of the 19
thcentury had at
least six children baptized in the community church.
Extensive data on cardiovascular risk factors, body com-
position, cognitive functioning, and blood chemistry are
available. These data were collected between 2002
and 2005. All participants gave informed consent and the
study was approved by the Medical Ethics Committee at
ErasmusMC.
Clinical and laboratory assessments
To deﬁne MetS, we used the deﬁnition proposed by the
National Cholesterol Education Program Adult Treatment
Panel (ATPIII) [4]. Waist circumference was measured
exactly halfway the distance between the lower costal
marginandtheiliaccrest[24].Bloodpressurewasmeasured
twice with an automatic device in a sitting position [25].
Blood was taken after fasting of at least 8 h. Insulin-
resistancewasdeterminedashomeostasismodelassessment
insulin-resistance (HOMA-IR) [26], which was computed
by multiplying fasting plasma insulin (micro-international
units per milliliter) and fasting plasma glucose (millimoles
per liter)/22.5. Total plasma adiponectin was analyzed with
the Human adiponectin RIA kit (cat.#: HADP-61HK) of
Linco Research. To measure total plasma CRP, we used the
US C-reactive protein ELISA (cat.# DSL-10-42100) of
Diagnostic Systems Laboratories, Inc.
We considered age, gender, smoking, alcohol use, edu-
cation, depression, and Apolipoprotein E genotype (APOE)
as possible confounders. Use of alcohol was deﬁned as
drinkingatleast1glasseachday.Educationwascategorized
in four groups: the ﬁrst group corresponding to 6 years of
education; the second to 7–10 years; the third to 11–
14 years; and the fourth to 15–18 years. Depressive symp-
toms were measured with the Hospital Anxiety and
Depression Scale (HADS-D). Genomic DNA was extracted
from whole blood samples, utilizing the salting out method.
Samples were genotyped for APOE with a Taqman allelic
discrimination Assay-By-Design (Applied Biosystems,
Foster City, CA). Insulin and adiponectin were only mea-
sured in a random subsample because of ﬁnancial con-
straints, therefore these data were not available for 721
participants.
Cognitive function
The battery of neuropsychological tests measured different
cognitive domains [27, 28]. General cognitive ability was
assessed with the Dutch Adult Reading Test (DART).
Memory function was measured with the auditory verbal
learning test from which four scores were derived:
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123immediate memory; learning; delayed recall, deﬁned as the
number of correctly recalled words after 20 min; and rec-
ognition, deﬁned as the number of correctly recognized and
correctly rejected words. Executive function was assessed
with the Trail Making Test parts A and B (TMT), the
Stroop Color and Word Test cards I, II and III, and verbal
ﬂuency tests. The TMT is a time-demanding task in which
participants are asked to connect a randomly placed
series of letters and numbers as quickly as possible [29]. In
TMT-A only the numbers have to be connected, in TMT-B
numbers and letters have to be connected alternately (from
1 to A, to 2 to B etc.). For analysis, we used time in seconds
depicted as the ratio of TMT-B/TMT-A. The Stroop Color
and Word Test is also a time demanding task consisting of
three cards. In card I, participants have to name the right
words as quickly as possible, in card II they have to name
the right colors as quickly as possible and in card III they
have to name the colors in which the words are printed as
quickly as possible. On this card the meaning of the word is
different than the color the word is printed in (e.g. blue is
written whereas the word is printed in red) [30]. For
analyses, we used time in seconds depicted as the ratios of
Stroop-III/Stroop-II. In the verbal ﬂuency tests, participants
had to name as many animals and as many words starting
with the same letter (D, A and T), each in 1 min. The score
was deﬁned as the total number of correct words on both
tasks. Lastly, visuo-spatial ability was assessed with the
WAIS-III block-design subtest. The test consists of repro-
ducing two-dimensional patterns using cubes that have red,
white, and half-red-half-white faces. The total number of
correctly reproduced blocks within a time limit was used as
a score.
In addition to analyzing individual test scores, three
composite scores were used: (1) memory (z-memory);
(2) executive function (z-executive); (3) global cognition
(z-global). These scores were computed by taking the
average of z-scores of the individual tests, which were
computed by subtracting the mean from the test score
divided by the standard deviation [31]. For time-demand-
ing tasks, the test score was subtracted from the mean. The
composite scores were only computed when at least 3
memory scores (z-memory), 2 executive scores (z-execu-
tive) and 6 total test scores (z-global) were available. In the
current study, we excluded participants who had a history
of stroke or dementia (N = 21) or were physically not able
to perform a neuropsychological test (N = 44). There were
10 participants with missing test scores due to technical
problems.
Statistical analysis
One large pedigree was extracted from the genealogical
database, which was cut into smaller pedigrees before
analyses with the software PedCut [32]. In total, 1,898
people with complete data could be linked to pedigrees with
a maximum bit size of 18 and these were included in the
analyses.
Baseline descriptive analyses were performed with SPSS
version 15.0, using the independent-samples T-test (con-
tinuous variables) or Chi-square statistics (categorical data).
C-reactive protein levels were transformed by taking the
common logarithm. Because high levels of CRP could have
been caused by acute inﬂammation, all values of the log-
transformed variable greater than three times the standard
deviation above the mean were excluded.
Possible confounders were ﬁrst analyzed as single
covariates in two regression models with either MetS or
cognitive test scores as dependent variables. Also, inter-
action terms of MetS, HOMA-IR, adiponectin and CRP
with age and sex were analyzed in these models. Covari-
ates that were signiﬁcantly associated were then entered
simultaneously into a model using backward regression.
We removed all covariates with a P-value[0.10. The
ﬁnal model included age, level of education, HADS-D
score, alcohol use and inbreeding coefﬁcient, which is a
measure of relatedness of the parents of an individual. The
analyses were stratiﬁed by sex, because the interaction
terms of MetS with sex were signiﬁcant.
Toidentifyassociationsbetweencognitivetestscoresand
MetS, HOMA-IR, adiponectin, and CRP, we performed
regressionanalysesusingtheSOLARsoftwareversion4.1.0
[33]. The MetS was included in the model as a binomial
variable, and additionally as a continuous variable ranging
from 0 to 5 to test the effect of increasing number of MetS
components. We used quartiles of HOMA-IR, adiponectin
and CRP with the lowest quartile as a reference category to
estimate the association with adipose tissue endocrine
function.
Results
The mean age of the study population was 47.7 (±14.3)
years in women and 49.2 (±14.1) years in men, with a
range of 18–86 years and less than 10% older than 67.
Metabolic syndrome was present in 227 (21%) women and
in 207 (25%) men. Of these, 155 women and 150 men
fulﬁlled three of the MetS diagnostic criteria, 63 and
54 fulﬁlled four and 9 and 3 fulﬁlled all ﬁve. Null criteria
were fulﬁlled by 282 women and 153 men. A comparison
of the individual MetS components is given in Table 1.
Table 2 shows the baseline characteristics of men and
women with and without MetS regarding determinants of
cognitive function and vascular and endocrine factors.
We studied the associations between MetS and cognitive
testscores.WomenwithMetShadsigniﬁcantlylowerscores
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123on Stroop en z-executive (P = 0.03 and P = 0.02) than
women without MetS (Table 3). An increasing number of
MetS components was associated to lower verbal ﬂuency
and z-executive scores (P = 0.04 and 0.02) in women. The
same trend, however non-signiﬁcant (P = 0.10), was seen
for Stroop.
The ﬁndings related to adipose tissue endocrine function
are given in Fig. 1 with analyses limited to executive
function. Women with high HOMA-IR scores had lower
scores on TMT, Stroop and z-executive than women with
low HOMA-IR scores. Higher adiponectin levels were
associated with higher scores on z-executive in both men
and women and with Stroop in women only. The associa-
tions of HOMA-IR with Stroop and z-executive were
more signiﬁcant (P = 0.004 and 0.007) when analyzing
HOMA-IR as continuous variables instead of quartiles. The
Table 1 Metabolic syndrome in the Erasmus rucphen family study (n = 1,898)
Men Women
MetS absent (n = 615) MetS present (n = 207) MetS absent (n = 849) MetS present (n = 227)
MetS components
Waist circumference (cm) 90.1 (9.5) 105.1 (9.3) 78.2 (9.5) 94.5 (10.2)
SBP (mm Hg) 140.7 (17.2) 151.2 (17.3) 131.2 (18.4) 152.9 (21.0)
DBP (mm Hg) 80.3 (9.5) 85.5 (9.4) 76.8 (9.3) 84.0 (10.0)
Use of antihypertensive medication (%) 11.7 34.3 9.0 38.3
Glucose (mmol/L, FPG) 4.6 (0.8) 5.2 (1.4) 4.3 (0.7) 5.1 (1.1)
Use of antidiabetic medication (%) 0.7 9.7 0.2 8.8
HDL-cholesterol (mmol/L) 1.2 (0.3) 0.9 (0.2) 1.5 (0.4) 1.2 (0.3)
Triglycerides (mmol/L) 1.2 (0.6) 2.3 (1.0) 1.1 (0.5) 1.8 (0.8)
Use of statins (%) 11.4 25.6 5.9 25.6
Values presented as mean (standard deviation). MetS = metabolic syndrome
Table 2 Metabolic Syndrome in relation to vascular and endocrine factors and determinants of cognitive function
Men Women
MetS absent (n = 615) MetS present (n = 207) MetS absent (n = 849) MetS present (n = 227)
Vascular and endocrine factors
Smoking (%) 32.7 33.5 46.5 45.1
Insulin (lU/ml, FPI) 11.8 (5.6) 19.1 (11.1)** 11.5 (4.7) 18.0 (9.2)**
HOMA-IR 2.4 (1.4) 4.5 (2.9)** 2.2 (1.0) 4.1 (2.4)**
Adiponectin (mg/L) 8.5 (4.2) 6.7 (3.7)** 13.1 (5.8) 9.5 (4.6)**
CRP (mg/L) 3.1 (6.2) 3.5 (5.8)** 3.4 (5.4) 5.1 (7.4)**
Determinants of cognitive function
Age (year) 47.4 (14.3) 54.4 (11.9) ** 45.3 (13.7) 56.7 (12.6)**
Education level (%) ** **
Low 30.0 37.7 26.2 46.9
Low-intermediate 37.9 44.4 42.0 40.7
High-intermediate 24.1 14.5 27.3 11.5
High 8.0 3.4 4.5 3.7
Alcohol (% frequent users) § 45.0 36.6 * 19.9 12.9*
HADS-D score 5.7 (4.0) 6.4 (3.8) * 5.4 (4.2) 7.6 (4.6)**
Apoe 4 allele carriers (%) 36.3 42.6 35.5 40.3
Values presented as mean (standard deviation)
MetS metabolic syndrome, FPG fasting plasma glucose, FPI fasting plasma insulin, HOMA-IR homeostatic assessment—insulin resistant model,
HADS-D Hospital Anxiety and Depression Scale, § deﬁned as drinking at least one unit of alcohol per day. * unadjusted P-value\0.05;
** unadjusted P-value\0.01
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123other associations, however, became non-signiﬁcant. No
association between CRP and executive function was found
in this population.
Discussion
The main ﬁnding of the current study is that MetS and
HOMA-IR is associated with poorer executive perfor-
mance in women.
There anumberoflimitationsofthe studytobediscussed
before interpretation of the ﬁndings.The differences
between persons with and without the MetS were relatively
small, which makes the clinical relevance or our ﬁndings
difﬁcult to predict. Also, we performed many tests.
Although statistically these tests are not independent, some
of the signiﬁcant P-values could be false-positive ﬁndings.
When applying strict Bonferonni adjustment, our results are
at best only borderline signiﬁcant (phoma-ir = 0.11). We did
not a priori have an hypothesis which of the different cog-
nitive outcomes were associated. The ﬁnding of a relation to
executive function but not to memory remains to be inter-
preted with caution. Although some are more consistent that
others, the consistent associations argue against false-posi-
tive ﬁndings. The cross-sectional design is another limita-
tion of our study, making it difﬁcult to assess causality.
Several longitudinal studies, however, suggest that MetS
mightbeacausative factorintherelationshipwithcognition
[34]. Another point to be discussed is that we studied the
relationship of MetS and cognition in a genetically isolated
population. We have taken relatedness into account by
adjusting for pedigree structure and relatedness, and since it
is a recently isolated population, the genetic makeup does
not differ largely from the general population and we do not
expect large differences in the effects of cardiovascular risk
factors on cognition [35]. As to the generalizaibility, there is
no reason to assume that the ﬁndings in terms of the etio-
logical pathways uncovered should not aply to outbred
populations. However, the associations may be more or less
pronounced in this family-based study. The strength of this
study is the population-based design in which participants
were not selected on the disease of interest. Also, the
inclusionofalargesamplesizeandarangeofcognitivetests
allowed detailed study of cognition.
Our ﬁndings of association of MetS with cognitive
performance conﬁrms previous cross-sectional and longi-
tudinal studies [22, 36, 37]. Although we studied different
cognitive domains, mainly executive function was associ-
ated with MetS. This is in line with two recent studies that
found signiﬁcant differences in processing speed, semantic
ﬂuency and executive function between persons with and
without MetS [38, 39]. Associations of the MetS with
Table 3 Association metabolic syndrome and cognitive function in men and women
Cognitive test Men Women
n MetS absent MetS present n MetS absent MetS present
General cognitive ability
Dutch adult reading test 750 62.1 (19.0) 58.3 (18.5) 993 60.4 (18.2) 52.6 (18.1)
Memory
AVLT—Working memory 757 4.3 (1.7) 3.9 (1.5) 999 4.6 (1.7) 4.0 (1.6)
AVLT—Learning 757 32.1 (8.9) 29.2 (8.3) 999 35.5 (8.9) 31.8 (8.9)
AVLT—Recognition 759 27.7 (2.2) 27.1 (2.5) 1,000 28.3 (2.2) 27.7 (2.4)
AVLT—Delayed recall 759 7.1 (2.9) 6.4 (2.8) 1,000 8.3 (2.9) 7.2 (2.9)
Executive
Ratio TMT-B/TMT-A
a 752 2.7 (1.0) 2.8 (1.0) 996 2.6 (1.0) 2.9 (1.1)
Ratio stroop III/stroop II
a 734 1.7 (0.4) 1.8 (0.4) 996 1.7 (0.3) 1.9 (0.6) *
Verbal ﬂuency 758 63.7 (18.0) 60.0 (17.1) 998 63.0 (17.9) 53.5 (18.7)
Visuospatial
Block design 756 30.8 (15.6) 25.7 (13.9) 998 28.7 (15.1) 20.8 (11.2)
Composite scores
Memory function 757 0.1 (0.8) -0.2 (0.8) 999 0.1 (0.8) -0.3 (0.9)
Executive function 759 0.1 (0.7) -0.1 (0.7) 998 0.1 (0.6) -0.4 (0.8) *
Global cognitive function 758 0.1 (0.7) -0.2 (0.6) 998 0.1 (0.7) -0.3 (0.7)
Values presented as mean (standard deviation). AVLT Adult Verbal Learning Test, TMT Trail Making Test, Stroop Stroop Color and Word Test
a time demanding task: high values represent low test scores
P = P-value derived from regression analysis adjusted for age, education, depressive score, alcohol use and family-relationship. * P\0.05
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123fronto-subcortical syndrome and with frontal white matter
changes were found by others [10, 40]. Damage to cerebral
small vessels could be one of the explanations for the
observed associations in the current study [41–43] and also
why we ﬁnd an association with executive function and not
memory.Anumberofstudiesﬁndthatanincreasingnumber
of MetS components is associated with lower cognitive
scores, whichisalsoconﬁrmed by ourobservations[10,37].
An effect of MetS components on the early development
of Alzheimer’s disease (AD) pathology may be another
possible mechanism underlying our observations, since the
insulin-degrading enzyme (IDE) functions less well in the
presence of insulin-resistance, resulting in higher levels of
amyloid b-peptide (Ab)[ 44, 45]. Long-term exposure to
insulin due to insulin-resistance, may by itself also have a
direct damaging effect on neurons [46]. Our observed
association of HOMA-IR and executive function is in line
with this.
Despite possible pathways through which adiponectin
could be linked to cognition, such as improvement of
insulin-sensitivity, anti-inﬂammatory effects and effects on
brain metabolism and the vascular system, our results do
not show a consistent association of adiponectin with
cognition [47, 48]. Adiponectin levels are however, lower
in individuals with MetS in our study and a trend was seen
with executive function in women, which supports further
study on the role of adiponectin in cognition.
Levels of CRP were not related to cognition in the
present study, however, data on other markers, such as
interleukin-6 (Il-6) and a1-antichymotrypsin (ACT) were
Fig. 1 Associations of HOMA-IR (a), adiponectin (b), and CRP
(c) with cognitive function in men and women Results are presented
as mean differences compared to quartile 1. The differences are
adjusted for age, education, depressive score, alcohol use and family-
relationship. HOMA-IR = homeostatis model assessment insulin-
resistance, CRP = C-reactive protein * P-value\0.05; ** P-value\
0.01
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123not available. These markers have been related to cognitive
decline and increased systemic inﬂammation has been
proposed as a possible modiﬁer between MetS and cogni-
tion [22]. We could not conﬁrm this, which may also be
due to a more pronounced effect of inﬂammation on cog-
nition in the elderly than in middle aged individuals.
Our study shows that there are gender differences in the
association of MetS with cognitive function. Gender-spe-
ciﬁc effects of metabolic components on cognitive function
have not extensively been addressed in previous studies,
while there is evidence that MetS has greater effect on
cardiovascular and cerebrovascular disease in women than
in men, indirectly supporting our observed differences
[49, 50]. Furthermore, there is evidence that men are
treated more aggressively for cardiovascular risk factors
[51]. As a consequence, men may be less likely to expe-
rience the adverse effects of MetS. Another factor that
could explain gender differences is depression, which is
highly correlated to cognition and more common in
women. Since our analyses were adjusted for depressive
symptoms, however, we do not think that depression
explains the observed differences in our study.
In summation, the most important ﬁndings of our study
are that MetS and HOMA-IR are associated with executive
function in women. We interpret these results with caution
due to the cross-sectional design and the potential problems
related to multiple testing. However, our study yields an
important starting point to replicate these ﬁndings and take
them further. Longitudinal studies will be needed to gain
insight in the causality of our reported ﬁndings and may
result in more conclusive ﬁndings.
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